CL2017000558A1 - Terapia de combinación - Google Patents
Terapia de combinaciónInfo
- Publication number
- CL2017000558A1 CL2017000558A1 CL2017000558A CL2017000558A CL2017000558A1 CL 2017000558 A1 CL2017000558 A1 CL 2017000558A1 CL 2017000558 A CL2017000558 A CL 2017000558A CL 2017000558 A CL2017000558 A CL 2017000558A CL 2017000558 A1 CL2017000558 A1 CL 2017000558A1
- Authority
- CL
- Chile
- Prior art keywords
- combination therapy
- effective amount
- formula
- combination
- neurodegenerative
- Prior art date
Links
- 238000002648 combination therapy Methods 0.000 title 1
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 abstract 1
- 208000010877 cognitive disease Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 230000000626 neurodegenerative effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- Endocrinology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Enzymes And Modification Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Massaging Devices (AREA)
Abstract
<p>LA PRESENTE INVENCIÓN PROPORCIONA UN MÉTODO PARA TRATAR UNA ENFERMEDAD NEURODEGENERATIVA O COGNITIVA, QUE COMPRENDE ADMINISTRAR A UN PACIENTE QUE NECESITE DICHO TRATAMIENTO UNA CANTIDAD EFICAZ DE UN COMPUESTO DE LA FÓRMULA:</p> <p>O UNA SAL FARMACÉUTICAMENTE ACEPTABLE DE ESTE; EN COMBINACIÓN CON UNA CANTIDAD EFICAZ DE UN ANTICUERPO MONOCLONAL ABETA ANTI-N3PGLU.</p>
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462050967P | 2014-09-16 | 2014-09-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2017000558A1 true CL2017000558A1 (es) | 2017-11-10 |
Family
ID=54207720
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2017000558A CL2017000558A1 (es) | 2014-09-16 | 2017-03-08 | Terapia de combinación |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US9999624B2 (es) |
| EP (1) | EP3193882A1 (es) |
| JP (1) | JP6339741B2 (es) |
| KR (1) | KR101871128B1 (es) |
| CN (1) | CN106687136A (es) |
| AP (1) | AP2017009794A0 (es) |
| AR (1) | AR101740A1 (es) |
| AU (1) | AU2015318257B2 (es) |
| BR (1) | BR112017003571A2 (es) |
| CA (1) | CA2956835A1 (es) |
| CL (1) | CL2017000558A1 (es) |
| CO (1) | CO2017001875A2 (es) |
| CR (1) | CR20170080A (es) |
| DO (1) | DOP2017000071A (es) |
| EA (1) | EA031764B1 (es) |
| EC (1) | ECSP17015977A (es) |
| IL (1) | IL250387A0 (es) |
| MX (1) | MX2017003414A (es) |
| NZ (1) | NZ728636A (es) |
| PE (1) | PE20170464A1 (es) |
| PH (1) | PH12017500493A1 (es) |
| SG (1) | SG11201701330PA (es) |
| SV (1) | SV2017005389A (es) |
| TN (1) | TN2017000072A1 (es) |
| TW (1) | TWI599358B (es) |
| WO (1) | WO2016043997A1 (es) |
| ZA (1) | ZA201700826B (es) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201742625A (zh) * | 2016-03-15 | 2017-12-16 | 阿斯特捷利康公司 | 組合療法 |
| TWI735600B (zh) * | 2016-07-01 | 2021-08-11 | 美商美國禮來大藥廠 | 抗－N3pGlu類澱粉β肽抗體及其用途 |
| US10034861B2 (en) | 2016-07-04 | 2018-07-31 | H. Lundbeck A/S | 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors |
| JP2019530647A (ja) * | 2016-08-18 | 2019-10-24 | イーライ リリー アンド カンパニー | Ｂａｃｅ−１阻害剤と抗ｎ３ｐｇｌｕ ａベータ抗体の併用療法 |
| AR110470A1 (es) * | 2016-10-21 | 2019-04-03 | Lilly Co Eli | Terapia de combinación para tratar la enfermedad de alzheimer |
| WO2018078042A1 (en) | 2016-10-28 | 2018-05-03 | H. Lundbeck A/S | Combination treatments comprising administration of imidazopyrazinones |
| JOP20190247A1 (ar) | 2017-04-20 | 2019-10-20 | Lilly Co Eli | أجسام بيتا ببتيد النشوانية المضادة لـ N3pGlu واستخداماتها |
| WO2019023247A1 (en) | 2017-07-25 | 2019-01-31 | Immutics, Inc. | TREATMENT OF CANCER BY BLOCKING THE INTERACTION OF TIM-3 AND ITS LIGAND |
| HRP20211784T1 (hr) | 2017-12-14 | 2022-02-18 | H. Lundbeck A/S | Kombinacijski tretmani koji se sastoje od primjene 1h-pirazolo[4,3-b]piridina |
| AR113926A1 (es) | 2017-12-14 | 2020-07-01 | H Lundbeck As | Derivados de 1h-pirazolo[4,3-b]piridinas |
| CN117447475A (zh) | 2017-12-20 | 2024-01-26 | H.隆德贝克有限公司 | 作为PDE1抑制剂的吡唑并[4,3-b]吡啶和咪唑并[1,5-a]嘧啶 |
| US12350278B2 (en) | 2018-06-27 | 2025-07-08 | Joshua O. Atiba | Therapy and prevention of prion protein complex infections in non-human animals |
| US10350226B1 (en) | 2018-06-27 | 2019-07-16 | Joshua O. Atiba | Therapy and prevention of prion protein complex infections |
| EP3918323A4 (en) | 2019-01-30 | 2022-12-28 | TrueBinding, Inc. | ANTI-GAL3 ANTIBODIES AND USES THEREOF |
| CN115443147A (zh) * | 2020-04-23 | 2022-12-06 | 伊莱利利公司 | 抗体的皮下吸收和生物利用度 |
| WO2021242776A2 (en) | 2020-05-26 | 2021-12-02 | Truebinding, Inc. | Methods of treating inflammatory diseases by blocking galectin-3 |
| CA3261511A1 (en) | 2022-07-29 | 2024-02-01 | Alector Llc | CD98HC ANTIGEN BINDING DOMAINS AND THEIR USES |
| CN119497721A (zh) | 2022-07-29 | 2025-02-21 | 艾莱克特有限责任公司 | 转铁蛋白受体抗原结合结构域及其用途 |
| WO2025166042A1 (en) | 2024-01-31 | 2025-08-07 | Alector Llc | Cd98hc antigen-binding domains and uses therefor |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4448134B2 (ja) | 2003-08-08 | 2010-04-07 | シェーリング コーポレイション | ベンズアミド置換基を有する環状アミンｂａｓｅ−１阻害剤 |
| US20100317850A1 (en) * | 2008-01-18 | 2010-12-16 | Yuichi Suzuki | Condensed aminodihydrothiazine derivative |
| PT3042917T (pt) * | 2010-08-12 | 2018-05-02 | Lilly Co Eli | Anticorpos do péptido beta amilóide anti-n3pglu e seus usos |
| GB201101140D0 (en) * | 2011-01-21 | 2011-03-09 | Eisai Ltd | Fused aminodihydrothiazine derivatives |
| TWI593692B (zh) | 2013-03-12 | 2017-08-01 | 美國禮來大藥廠 | 四氫吡咯并噻嗪化合物 |
-
2015
- 2015-09-01 TW TW104128851A patent/TWI599358B/zh not_active IP Right Cessation
- 2015-09-02 AR ARP150102803A patent/AR101740A1/es unknown
- 2015-09-08 BR BR112017003571A patent/BR112017003571A2/pt not_active Application Discontinuation
- 2015-09-08 CA CA2956835A patent/CA2956835A1/en not_active Abandoned
- 2015-09-08 EA EA201790305A patent/EA031764B1/ru not_active IP Right Cessation
- 2015-09-08 CN CN201580049574.0A patent/CN106687136A/zh active Pending
- 2015-09-08 SG SG11201701330PA patent/SG11201701330PA/en unknown
- 2015-09-08 KR KR1020177006748A patent/KR101871128B1/ko not_active Expired - Fee Related
- 2015-09-08 US US15/503,027 patent/US9999624B2/en not_active Expired - Fee Related
- 2015-09-08 EP EP15771800.8A patent/EP3193882A1/en not_active Withdrawn
- 2015-09-08 AP AP2017009794A patent/AP2017009794A0/en unknown
- 2015-09-08 CR CR20170080A patent/CR20170080A/es unknown
- 2015-09-08 JP JP2017514623A patent/JP6339741B2/ja not_active Expired - Fee Related
- 2015-09-08 MX MX2017003414A patent/MX2017003414A/es unknown
- 2015-09-08 WO PCT/US2015/048807 patent/WO2016043997A1/en not_active Ceased
- 2015-09-08 TN TN2017000072A patent/TN2017000072A1/en unknown
- 2015-09-08 NZ NZ728636A patent/NZ728636A/en not_active IP Right Cessation
- 2015-09-08 AU AU2015318257A patent/AU2015318257B2/en not_active Ceased
- 2015-09-08 PE PE2017000406A patent/PE20170464A1/es unknown
-
2017
- 2017-02-01 IL IL250387A patent/IL250387A0/en unknown
- 2017-02-02 ZA ZA2017/00826A patent/ZA201700826B/en unknown
- 2017-02-22 SV SV2017005389A patent/SV2017005389A/es unknown
- 2017-02-24 CO CONC2017/0001875A patent/CO2017001875A2/es unknown
- 2017-03-08 CL CL2017000558A patent/CL2017000558A1/es unknown
- 2017-03-14 DO DO2017000071A patent/DOP2017000071A/es unknown
- 2017-03-15 PH PH12017500493A patent/PH12017500493A1/en unknown
- 2017-03-15 EC ECIEPI201715977A patent/ECSP17015977A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PH12017500493A1 (en) | 2017-08-07 |
| ECSP17015977A (es) | 2018-03-31 |
| AP2017009794A0 (en) | 2017-03-31 |
| ZA201700826B (en) | 2018-12-19 |
| SG11201701330PA (en) | 2017-04-27 |
| DOP2017000071A (es) | 2017-06-15 |
| CR20170080A (es) | 2017-03-30 |
| EA201790305A1 (ru) | 2017-07-31 |
| EA031764B1 (ru) | 2019-02-28 |
| US20170224702A1 (en) | 2017-08-10 |
| SV2017005389A (es) | 2018-01-17 |
| BR112017003571A2 (pt) | 2017-12-19 |
| TW201618786A (zh) | 2016-06-01 |
| CN106687136A (zh) | 2017-05-17 |
| EP3193882A1 (en) | 2017-07-26 |
| KR101871128B1 (ko) | 2018-06-25 |
| AU2015318257A1 (en) | 2017-02-16 |
| CO2017001875A2 (es) | 2017-05-19 |
| TN2017000072A1 (en) | 2018-07-04 |
| PE20170464A1 (es) | 2017-04-26 |
| US9999624B2 (en) | 2018-06-19 |
| CA2956835A1 (en) | 2016-03-24 |
| KR20170036103A (ko) | 2017-03-31 |
| TWI599358B (zh) | 2017-09-21 |
| NZ728636A (en) | 2018-05-25 |
| JP6339741B2 (ja) | 2018-06-06 |
| AR101740A1 (es) | 2017-01-11 |
| AU2015318257B2 (en) | 2018-06-14 |
| IL250387A0 (en) | 2017-03-30 |
| WO2016043997A1 (en) | 2016-03-24 |
| MX2017003414A (es) | 2017-06-19 |
| JP2017529348A (ja) | 2017-10-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2017000558A1 (es) | Terapia de combinación | |
| CL2017000285A1 (es) | Terapia combinada para el tratamiento de un paramixovirus | |
| IL277215A (en) | Use of anti-IL-36R antibodies to treat generalized purulent urticaria | |
| CL2017000335A1 (es) | Tratamientos conjuntos con anticuerpos anti cd40 | |
| BR112017022838A2 (pt) | receptores quiméricos de antígeno de antígenos de mieloma kappa e seus usos | |
| BR112016019871A2 (pt) | anticorpos anti-cd38 para o tratamento de leucemia linfoblástica aguda | |
| BR112018014016A2 (pt) | combinação de um agonista de ox40 e um agonista de anticorpo monoclonal 4-1bb para tratamento de câncer | |
| EA201990296A1 (ru) | Антитела против siglec-7 для лечения рака | |
| MX370818B (es) | Anticuerpos anti-b7-h1 para tratar tumores. | |
| CL2016001979A1 (es) | Métodos de tratamiento de enfermedad de alzheimer. | |
| EA201790569A1 (ru) | Антитела и иммуноконъюгаты против cll-1 | |
| HUE053239T2 (hu) | Humanizált tau-ellenanyagok Alzheimer-kór kezelésére | |
| MX2018008105A (es) | Compuestos inhibidores de metaloenzima. | |
| LT3416631T (lt) | Terapiniai agentai, skirti neurodegeneracinių ligų gydymui | |
| MX2019011423A (es) | Metodos de tratamiento de enfermedades neurodegenerativas. | |
| DOP2017000120A (es) | 4-oxo-3,4-dihidro-1,2,3-benzotriazinas como moduladores de gpr139 | |
| CL2017002983A1 (es) | Terapia combinada de un anticuerpo anti-cd-20 con un inhibidor de bcl-2 y un inhibidor de mdm2 | |
| MX382904B (es) | Combinaciones de fármacos para tratar mieloma múltiple. | |
| IL287832A (en) | Methods of administering anti-cd38 antibody to treat multiple myeloma | |
| MX2017011272A (es) | Metodo de tratamiento para la colangitis esclerosante primaria. | |
| CY1122784T1 (el) | Αλογονωμενες κιναζολιν-τηf-αμινες ως αναστολεις του ρdε1 | |
| CL2019003485A1 (es) | Métodos para redicur la proteinuria en un sujeto humano que padece de nefropatía por inmunoglobulina a. (divisional solicitud 201900909) | |
| PT3630177T (pt) | Paradigma de tratamento para um tratamento combinado de anticorpo anti cd19 e venetoclax | |
| PL3463328T3 (pl) | Seladelpar do leczenia pierwotnego zapalenia dróg żółciowych | |
| BR112018013256A2 (pt) | anticorpo para pcsk9, fragmento de ligação a antí-geno do mesmo e aplicação médica do mesmo |